Peer-reviewed veterinary case report
Treatment options for feline infectious peritonitis and COVID-19
By Izes, Aaron M et al.·Published in The veterinary quarterly·2020·Sydney School of Veterinary Science, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats.
- Species:
- cat
Plain-English summary
A cat with feline infectious peritonitis (FIP), a serious viral disease, has limited treatment options. Traditional treatments have not been effective, but recent studies show promise with two antiviral drugs, GC376 and GS-441524, which have improved survival rates and even cured some cats. Unfortunately, these medications are not yet widely available for veterinarians to prescribe. As a result, FIP remains a difficult condition to manage, but ongoing research is hopeful for better treatments in the future.
People also search for: cat FIP treatment options · feline coronavirus symptoms · antiviral drugs for cats
Abstract
Feline infectious peritonitis (FIP) is a viral-induced, immune-mediated disease of cats caused by virulent biotypes of feline coronaviruses (FCoV), known as the feline infectious peritonitis virus (FIPV). Historically, three major pharmacological approaches have been employed to treat FIP: (1) immunomodulators to stimulate the patient's immune system non-specifically to reduce the clinical effects of the virus through a robust immune response, (2) immunosuppressive agents to dampen clinical signs temporarily, and (3) re-purposed human antiviral drugs, all of which have been unsuccessful to date in providing reliable efficacious treatment options for FIPV. Recently, antiviral studies investigating the broad-spectrum coronavirus protease inhibitor, GC376, and the adenosine nucleoside analogue GS-441524, have resulted in increased survival rates and clinical cure in many patients. However, prescriber access to these antiviral therapies is currently problematic as they have not yet obtained registration for veterinary use. Consequently, FIP remains challenging to treat. The purpose of this review is to provide an update on the current status of therapeutics for FIP. Additionally, due to interest in coronaviruses resulting from the current human pandemic, this review provides information on domesticated cats identified as SARS-CoV-2 positive.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33138721/